Liver/Biliary

Increased Hospitalization and Mortality in Patients With COVID-19 and Pre-existing Liver Disease

More than half of patients with COVID-19 have markers of liver injury, researchers report in Gastroenterology. However, patients with pre-existing liver disease, and even more so those with cirrhosis, have increased risks for hospitalizations and death, the study found. Shailendra Singh and Ahmad Khan studied the effects pre-existing liver disease

Read more
  • Gastroparesis Caused by Hepatitis A Virus Infection

Gastroparesis Caused by Hepatitis A Virus Infection

Researchers describe a rare case of infectious gastroparesis caused by hepatitis A virus infection in the December issue of Gastroenterology. Amrit K. Kamboj et al report the case of a 33-year-old woman with a 10-day history of painless jaundice, decreased appetite, malaise, and pruritus. The patient did not have right

Read more
  • What are the Risk Factors for Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes?

What are the Risk Factors for Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes?

Persons with type 2 diabetes have a more than 2-fold increase in risk for severe liver disease, researchers report in the December issue of Clinical Gastroenterology and Hepatology. The authors found risk factors that might be used to identify persons with type 2 diabetes who should be screened for liver disease.

Read more
  • Does DAA Therapy for HCV Infection Increase Survival in Patients Who Have Responded to Treatment for Hepatocellular Carcinoma?

Does DAA Therapy for HCV Infection Increase Survival in Patients Who Have Responded to Treatment for Hepatocellular Carcinoma?

In patients who have received successful treatment for HCV-related hepatocellular carcinoma (HCC), eradication of the HCV infection with direct-acting antiviral (DAA) significantly reduces risk of death, researchers report in the November issue of Gastroenterology. Chronic hepatitis C virus (HCV) infection is the most common cause of HCC in North America and Europe. DAA

Read more
  • Does Placement on a Distant Liver Waitlist Increase Chances of Transplantation?

Does Placement on a Distant Liver Waitlist Increase Chances of Transplantation?

Placement on a liver transplant waitlist outside of a patient’s home region can reduce mortality and increase odds of receiving a liver, researchers report in the October issue of Clinical Gastroenterology and Hepatology. Strategies are needed to overcome geographic differences in access to livers for transplantation, which are more likely

Read more
  • How Should We Treat Recurrent Acute Pancreatitis?

How Should We Treat Recurrent Acute Pancreatitis?

Recurrent acute pancreatitis with a clear cause can be treated with endoscopy, explain Liam Zakko and Timothy B. Gardner in a “Here and Now: Clinical Practice” article in the October issue of Clinical Gastroenterology and Hepatology. Acute pancreatitis affects 40 to 50 of every 100,000 Americans per year and is the

Read more
  • How Does Alpha-1 Antitrypsin Deficiency Affect the Liver?

How Does Alpha-1 Antitrypsin Deficiency Affect the Liver?

Adults with a severe form of alpha-1 antitrypsin deficiency (AATD) caused by the Pi*Z mutation, and mice with the same genetic alteration, can have liver steatosis and impaired lipid secretion, researchers report in the September issue of Gastroenterology. The research team found factors associated with significant liver fibrosis in patients

Read more
  • Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

The efficacy of 48 weeks treatment with besifovir dipivoxil maleate (BSV) for chronic hepatitis B virus (HBV) infection is comparable to that of tenofovir disoproxil fumarate (TDF), with durable effects for 96 weeks, researchers report in the August issue of Clinical Gastroenterology and Hepatology. BSV has a better safety profile

Read more
  • Why Are Patients Cured of HCV Infection Still at Risk for Liver Cancer?

Why Are Patients Cured of HCV Infection Still at Risk for Liver Cancer?

Chronic infection with the hepatitis C virus (HCV) causes epigenetic changes in liver cells that alter gene expression patterns and continue to affect risk for hepatocellular carcinoma (HCC), regardless of patients’ response to direct-activating antiviral (DAA) agents, researchers report in the June issue of Gastroenterology. These alterations might be targeted

Read more
  • Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia and Chronic Liver Disease

Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia and Chronic Liver Disease

Lusutrombopag, an oral small molecule agonist of the thrombopoietin receptor, achieves and maintains target platelet count in patients with chronic liver disease and thrombocytopenia undergoing invasive procedures, researchers report in a phase 3, placebo-controlled trial published in the May issue of Clinical Gastroenterology and Hepatology. The drug caused no significant

Read more